Interested parties may listen to the audio part of the conference call by dialing toll-free (877)-407-3140 in the U.S. and Canada, and (201) 689-8473 outside the U.S. and Canada.
An audio/slide webcast of the conference call, real-time or archived, will be viewable by going to Inovio’s website, www.inovio.com, and clicking on "Conference Call." The archived version will be available until December 14, 2010. A replay of the audio-only part of the conference call will be available through September 27, 2010, by dialing toll-free (877) 660-6853 in the U.S. and Canada, and (201) 612-7415 outside the U.S. and Canada, and entering both the account (#286) and the conference ID (#356576).
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. The company’s SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio’s proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic), avian flu, and HIV vaccines (both preventive and therapeutic). Inovio is developing its universal influenza vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com http://www.inovio.com.
